Prof G Markets: "EV Tax Credit Comes to an End & Why Trump Rx Will Not Fix High Drug Costs"

Episode Date: October 2, 2025
Host: Ed Elson
Guest: John McNeil (CEO, DVX Ventures; Former President of Tesla; GM Board Member)
Segment Expert: Courtney Breen (Senior Analyst, Bernstein Research)

Overview of the Episode

This episode of Prof G Markets explores two key stories shaping markets and public policy:

• The end of the U.S. federal electric vehicle (EV) tax credit and its implications for the auto industry, consumers, and global competition, with expert insights from John McNeil.
• President Trump's "Trump Rx" plan aimed at bringing down prescription drug costs, analyzed in depth with healthcare analyst Courtney Breen.

Throughout, host Ed Elson delivers sharp analysis on market movements, policy changes, and the underlying forces shaping these headline stories.

Key Discussion Points & Insights

1. Markets Update and the End of the EV Tax Credit

[02:04]–[04:17]

• Market Recap:
  S&P 500 and Dow hit record highs on optimism that the government shutdown will be short-lived; treasury yields fell; ADP employment report indicated contracting private sector payrolls, supporting possible Fed rate cuts. Gold continues climbing.

• EV Tax Credit Ends:
  As of the episode’s air date, the $7,500 federal EV tax credit officially expired due to the Republican tax bill passed in July. EV sales surged before expiration, with electric vehicles capturing a record 12% of new vehicle sales in September and Tesla posting its best quarter of the year.

• Key Questions Raised:

  • What happens to EV prices and demand post-credit?
  • What is the impact on companies like Tesla?
  • How does this affect American competitiveness, especially with China?

2. Electric Vehicles Without Federal Support: Industry Outlook

Interview with John McNeil
[04:17]–[17:14]

a) Impact on Pricing and Margins

[04:18]–[06:57]

• John McNeil:
  The US will likely mirror Europe, where subsidy removals produced a temporary drop, but long-term growth of EVs continued. The market trajectory will be “up and to the right, but it’s choppy…not a linear curve.”

  “Consumers…have a lot of choice… like 65 different models in the EV market that we didn’t have two years ago.” — John McNeil [05:29]

• On Price Increases:
  The burden will be split—some costs absorbed by automakers through incentives (compressing margins), some by customers via higher prices. More incentives likely at the lower end of the market.

b) Does the Market Still Need a Subsidy?

[06:57]–[08:25]

• Industry Sentiment:
  EV market is increasingly established—"one out of every four vehicles sold in the US is now electrified."

  “Had this happened two or three years ago, it would have had probably a very significant effect on the industry. But now…we’re able to bring the cost curve down.” — John McNeil [07:46]

c) U.S.–China Competition

[08:25]–[10:43]

• Pressure from China:
  Chinese EVs (like BYD) are much cheaper due to government subsidies, raising questions about U.S. competitiveness.

  “The US industry cannot settle for just being a North American regional player. We want to be able to export and compete too.” — John McNeil [10:34]

d) The Chinese Model: BYD and Industrial Policy

[10:43]–[12:54]

• On BYD:
  China’s policy subsidizes many players, lets “the best of the best emerge," then consolidates under winners for global export. “The reason that BYD’s sales went down…there’s been a price war in China. The government called timeout…and said, you need to stop this and raise prices.” — John McNeil [11:45]

e) Strategic Importance of Electrification for GM

[12:54]–[15:14]

• Electrification as “North Star”:
  Despite subsidy loss, electrification is central to GM’s future strategy, based on long-term consumer benefits (cheaper fuel, lower maintenance, improved handling).

f) Tesla: Beyond Cars

[15:14]–[17:14]

• Tesla’s Future:
  The company is consciously shifting to focus on autonomy and robotics.

  “I think Elon came back from China…and essentially said…the car business is lost and we need to now move on…and the existential products are autonomy and robotics. That’s the future…” — John McNeil [15:44]

  • “They’re guiding down in terms of the quarterly expectations of deliveries…really focused on an autonomous future.”
  • “It’s a car company in transition.” — John McNeil [16:42]

3. Trump Rx & Drug Pricing Policy

[20:01]–[29:32]

a) What is Trump Rx?

• A government-run website for consumers to buy drugs directly from manufacturers.
• Launch includes a deal with Pfizer to offer discounts and to provide Medicaid patients with “most favored nation” pricing.

b) Is Trump Rx a Real Solution?

Interview: Claire Miller & Courtney Breen (Bernstein Research)

• Root Causes Remain:

  “Is this one step going to change the outcome? Not necessarily on a broad base…This could be a good channel for a patient…that can’t get access through insurance today. But…for many patients…for this to be the silver bullet solution [it isn’t].” — Courtney Breen [20:55–22:46]

• Pfizer’s Incentives:

  “In some ways, this was an opportunity for the industry to get on the front foot…[working] with this administration…to ensure enough profit so they can invest…in future innovation.” — Courtney Breen [23:11–24:15]

• Sector Impact:

  • Investors relieved to see a framework for negotiations, avoiding worst-case revenue scenarios.
  • Expect more deals with other companies.

• Key Limitations:

  • Actual impact depends on which drugs are listed.
  • Example cited: “the only drugs [named] are really pretty insignificant to the Pfizer portfolio.” — Ed Elson [29:07]

  “Trump Rx might have an impact for some people, but we won’t know the scale…until we actually see what drugs are listed.” — Claire Miller [26:11]

c) Winners and Losers

• Short-term, the biggest “winners” appear to be drug companies (who avoid harsh tariffs) rather than patients [27:36].

• Long-term Balance:

  • Industry needs profits to innovate and tackle major diseases, but avoids “exploitation” in pricing.

  “Taking a drug from discovery through to the end…about $2 billion. And very, very few drugs make it.” — Courtney Breen [28:33–29:32]

4. Ed Elson’s Final Analysis

[29:37]–[35:54]

• Policy Context:

  • While Trump Rx makes a good headline, real crisis is in the broader healthcare system—specifically, the battle over health insurance subsidies in Congress.
  • Potential for massive price hikes (75%–136%) in health insurance premiums if subsidies are not renewed.
  • Policy tension: discounts on a few drugs may be dwarfed by the far greater impact of rising insurance costs and Medicaid cuts.

  “The idea that the cost of certain eczema drugs will come down by 50%…but health insurance premiums for the rest of America are going to double…suddenly that 50% discount doesn’t seem to really matter anymore.” — Ed Elson [31:55]

  “You have to look at this issue in an incredibly narrow way. You basically need to look at it through a straw. And that’s how Trump wants us to look at all these deals.” — Ed Elson [33:09]

  • Ultimately, the episode frames Trump Rx as a distraction from the deeper explosion in healthcare costs.

Notable Quotes & Memorable Moments

• John McNeil (on EV market resilience):
  “When you look over the long run, the curve is up and to the right, but it's choppy.” [04:52]

• John McNeil (on China’s approach):
  “They start almost a Darwinian approach where they fund and subsidize 100 players…The second chapter is the winners get cheap capacity, free capacity and makes them even more competitive.” [11:24]

• Ed Elson (on the larger health policy story): “This whole Trump Rx-Pfizer situation starts to look a little bit insignificant, bordering on ridiculous.” [32:03]

• Courtney Breen (on innovation/limitations): “Taking a drug from discovery through to the end of the journey, about $2 billion. And very, very few drugs make it.” [29:02]

Timestamps for Major Segments

• EV Tax Credit News & Analysis: [02:04]–[17:14]
• Interview with John McNeil: [04:17]–[17:14]
• Introduction to Trump Rx & Healthcare Reform: [20:01]–[21:00]
• Courtney Breen Interview: [20:45]–[29:32]
• Ed Elson’s Closing Analysis & Policy Rant: [29:37]–[35:54]

Tone and Language

• The conversation is sharp, frank, and at times wry—typical of Prof G Markets’ “no mercy, no malice” brand.
• Technical details and industry data are paired with strong points of view, especially in Ed Elson’s closing segment.

Final Takeaway

While headline policies like the end of the EV tax credit or the launch of Trump Rx spark flashy market reactions, Prof G Markets uncovers the complex and sometimes contradictory realities beneath: the EV market’s maturing resilience amid global competition, and the stark disconnect between drug price PR moves and the vast, systemic pressures driving American healthcare costs. For listeners, the message is clear: in a capitalist society, headlines often obscure bigger trends and deeper forces at play.

For further questions or comments, listeners are invited to contact: markets@profgmedia.com